Skip to main content

Viloxazine News

Many ADHD Medications Lead to Increases in Blood Pressure and Heart Rate

MONDAY, April 21, 2025 – Many pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD) lead to increases in hemodynamic signs, including blood pressure and pulse, according to...

ADHD Drugs Generally Safe For Heart Health, Review Says

MONDAY, April 14, 2025 – Worried about taking the ADHD meds you’ve been prescribed because they might harm your heart health? There’s no need to fret, according to a new evidence review. ADHD med...

Supernus Announces FDA Approval of Qelbree for the Treatment of ADHD in Adults

First novel, nonstimulant option for adults with ADHD in 20 years ADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) – Supernus...

FDA Approves Qelbree (viloxazine) for the Treatment of ADHD

ROCKVILLE, Md., April 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Attention-Deficit Hyperactivity Disorder (ADHD)

Viloxazine patient information at Drugs.com